CSC
VXRT

Caldwell Sutter Capital’s Vaxart VXRT Stock Holding History

Caldwell Sutter Capital’s Portfolio VXRT Stock Details VXRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,000
Closed -$904 – 893
2025
Q2 		$904 Hold
2,000
– – ﹤0.01% 779
2025
Q1 		$814 Buy
+2,000
New +$1.28K ﹤0.01% 807

Other funds holding VXRT

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
CFO
Custos Family Office Austin, Texas $147M AUM 17.83% 1-Year Est. Return
LCM
LVM Capital Management Portage, Michigan $1.19B AUM 41.5% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.56B AUM 19.48% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Caldwell Sutter Capital's VXRT Position: Q3 2025 in Review

Caldwell Sutter Capital sold out of Vaxart (VXRT) in Q3 2025, closing a stake of 2,000 shares — an estimated $904 sold.

Caldwell Sutter Capital first reported a position in VXRT in Q1 2025 and held it in 2 quarters. The position peaked at $904 in Q2 2025. 17 funds tracked by Wall St. Rank hold VXRT as of Q3 2025.

  • Caldwell Sutter Capital reported no remaining Vaxart position as of Q3 2025 after selling out during the quarter.
  • Caldwell Sutter Capital sold 2,000 Vaxart shares in Q3 2025, an estimated $904.
  • Caldwell Sutter Capital first reported a position in Vaxart in Q1 2025 and held it in 2 quarters.
  • Caldwell Sutter Capital's Vaxart position peaked at $904 in Q2 2025.
  • 17 funds tracked by Wall St. Rank held Vaxart as of Q3 2025.

Based on Caldwell Sutter Capital's 13F filing for Q3 2025, filed 29 Oct 2025.